Next CERIC Seminar
January 19th, CMM Lecture Hall (L8:00)
Speaker: Peter Szodoray, Oslo University Hospital, Department of Immunology
Title: The role of CD45 in B cell tolerance and humoral immune effector function
Host: Marie Wahren-Herlenius
Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection
Linda Labberton, Ellinor Kenne, Andy T. Long, Katrin F. Nickel, Antonio Di Gennaro, Rachel A. Rigg, James S. Hernandez, Lynn Butler, Coen Maas, Evi X. Stavrou & Thomas Renné. Nature Communications 2016 6;7:12616
CERIC's goal is to be an internationally leading center in chronic inflammation, the pathological process that links inflammatory disorders such as multiple sclerosis, rheumatoid arthritis and psoriasis with atherosclerotic cardiovascular disease. For this purpose, we will build on existing, strong research in inflammatory mediators, autoimmunity , chronic inflammatory diseases, and cardiovascular disease at the Karolinska Institutet.
The following research aims will be addressed:
Aim 1: To determine why chronic inflammation sometimes, but not always, results in increased atherosclerosis and leads to myocardial infarction or stroke (cardiovascular disease).
Aim 2: To identify novel therapy targets and investigate the effects of targeted therapies against chronic inflammatory diseases and cardiovascualr diseases
Taken together, these two approaches will allow us to both understand the etiology and pathogenesis of chronic inflammatory diseases and cardiovascular disease and provide a basis for improved prevention and therapy for chronic inflammatory diseases and inflammatory cardiovascular disease, two major challenges to health in the population.